Free Trial
OTCMKTS:GTHP

Guided Therapeutics Q2 2026 Earnings Results & Report

Guided Therapeutics logo
$0.18 -0.02 (-10.00%)
As of 10/9/2026 01:51 PM Eastern

Guided Therapeutics reported Q2 2026 earnings on August 13, 2026. The company reported EPS of -$0.01.

Earnings Announcement Details

Quarter
Q2 2026
Report Date

Guided Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Guided Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Guided Therapeutics Q2 2026 Earnings FAQ

Guided Therapeutics (OTCMKTS:GTHP) reported earnings of -$0.01 per share for Q2 2026. The report was announced on Thursday, August 13, 2026.

Guided Therapeutics Earnings Headlines

Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
See More Guided Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Guided Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guided Therapeutics and other key companies, straight to your email.

About Guided Therapeutics

Guided Therapeutics (OTCMKTS:GTHP), Inc. is a medical technology company focused on developing diagnostic products for women’s health. The company’s primary focus has been the detection of cervical disease and cancer using minimally invasive or non-invasive technologies.

Its lead product, LuViva Advanced Cervical Scan, is designed to evaluate cervical tissue using optical spectroscopy. The system analyzes changes in tissue characteristics that may be associated with precancerous or cancerous conditions and is intended to help clinicians identify patients who may require additional evaluation, including biopsy.

Guided Therapeutics has pursued regulatory and commercial opportunities for its cervical disease detection technology in the United States and international markets. The company is headquartered in Georgia and has historically focused its operations on developing, validating and commercializing diagnostic devices rather than providing direct medical care.

View Guided Therapeutics Profile